Abattis Bioceuticals (ATTBF) 0.0270 $ATTBF
Abattis Names Michael Yung as Ceo
ACCESSWIRE - Mon Apr 25, 7:06AM CDT
VANCOUVER, BC / ACCESSWIRE / April 25, 2016 / Abattis Bioceuticals Corp. (OTC PINK: ATTBF) (CSE: ATT), (the "Company" or "Abattis"
, today announced that Michael Yung has been named as Chief Executive Officer (CEO) of Abattis Bioceuticals Corp, effective April 18, 2016. He will succeed William (Bill) Fleming, who has resigned his role as CEO and Director to pursue other business interests.
Abattis Announces Co-Formulation with Vitagum(TM)
ACCESSWIRE - Mon Apr 18, 7:07AM CDT
VANCOUVER, BC / ACCESSWIRE / April 18, 2016 / Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB : ATTBF) ("Abattis" through its proposed licensing arrangement with Crimson Capital Group ("Crimson" is pleased to announce that a letter of intent to co-formulate gum products under the brand name Vitagum™ has now been signed.
Abattis Receives NPN from Health Canada for Phyto(NOS)(TM)
ACCESSWIRE - Tue Apr 12, 7:08AM CDT
VANCOUVER, BC / ACCESSWIRE / April 12, 2016 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) ("Abattis" is pleased to announce that it has received a Natural Product Number ("NPN" approval for Phyto(NOS)™. This NPN allows Abattis to manufacture and to sell Phyto(NOS)™ in Canada. Ingredient Identity of Santa Ana, California, completed the claim substantiation report necessary for the sale of Phyto(NOS)™ in the United States.
Abattis Agrees to License Its NOXX Botanical Blends Products
ACCESSWIRE - Wed Apr 06, 9:56AM CDT
VANCOUVER, BC / ACCESSWIRE / April 6, 2016 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) ("Abattis' has agreed to enter a licensing arrangement and marketing partnership with Crimson Capital Group ("Crimson" to commercialize Abattis' NÖXX Botanical Blends Products, which contain Abattis' patent-pending Phyto(NOS)™.
Fronsac REIT Announces a Change to the Board of Trustees
Marketwired - Thu Mar 31, 9:45AM CDT
(TSX VENTURE: GAZ.UN) Fronsac Real Estate Investment Trust ("Fronsac REIT" or "Fronsac" today announced that Guy P. Dancosse and Francois-Olivier Laplante have been appointed to the Fronsac board of trustees. We are pleased to welcome these new trustees to our team and believe that these additions to the board will compliment existing talent and provide added guidance and experience as we continue to grow.
IIROC Trade Resumption - ATT
CNW Group - Mon Nov 16, 9:40AM CST
Trading resumes in:
IIROC Trading Halt - ATT
CNW Group - Mon Nov 16, 9:14AM CST
The following issues have been halted by IIROC:
Cabinet Grow: Real Revenue, Real Potential
ACCESSWIRE - Tue Nov 03, 8:20AM CST
SEATTLE, WA / ACCESSWIRE / November 3, 2015 / The U.S. cannabis industry could be worth $35 billion by 2020, according to GreenWave Advisors, if the federal government ended prohibition. In a more conservative model, the analyst believes that the market could still exceed $20 billion, with 12 states and Washington DC legalizing adult-use cannabis and 37 states legalizing medical marijuana. The rapid growth and scale comes from a combination of state programs and home-grow legalization initiatives.
North America Cannabis Market: Focus on Application, Derivative, and Region - Estimation & Forecast, 2015-2020
M2 - Mon Sep 14, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n7wcc2/north_america) has announced the addition of the "North America Cannabis Market: Focus on Application, Derivative, and Region - Estimation & Forecast, 2015-2020" report to their offering. The North America Cannabis market is poised to grow from $ 3.46 billion in 2014 to $20.67 billion in 2020 at an estimated CAGR of 29.80% from 2015 to 2020. Factors like multifaceted applications of cannabis, expansion of licensing strategies, and automated irrigation system among others are driving this market towards growth. This market is also tackling some issues like volatile regulatory framework, absence of market leaders, perception towards marijuana, and environmental hazards among others. Owing to the fragmented supply chain and the presence of black market and perception issues, the cannabis market in North America has been estimated and forecasted strictly for the legal states, both for marijuana and hemp. The following pointers will encompass the scope of the research study and will lend a better understanding to the reader: - The total cannabis market is inclusive of the two primary derivatives namely-marijuana and Industrial Hemp - The market estimation for marijuana includes revenue from the legalized and active markets and Canada, where only medical marijuana is legalized - Certain states have legalized medical and recreational marijuana after 2013, however, there markets are not yet active and therefore, their market shares are not included in the total market size for the benchmark year (2014) - The report includes revenue for the marijuana market for all the active states having market share of above 0.5%. Rest of the state's revenue are clubbed as others - Through the forecast period, the other' states segment will also include the revenue from further states that are anticipated to legalize medical marijuana - The market size by application has been further segmented as applications of marijuana and industrial hemp for better clarity - The report includes the estimates of different entities of the cannabis ecosystem - The report also includes the optimistic revenue estimate for the benchmark year only for the U.S - Tax revenue estimate in case when marijuana is legalized across all the states in the U.S. has also been included Key Topics Covered: 1 Research Methodology, Scope And Coverage 2 Executive Summary 3 Introduction To North American Cannabis Market 4 Key Strategies And Development In The North American Cannabis Market (2013-2015) 5 Market Dynamics 6 North America Cannabis Industry Analysis 7 Regulatory & Legal Framework, Consortiums And Compliances 8 Market Sizing - Estimation, Analysis & Forecast By Derivative 9 Market Sizing- Estimation, Analysis & Forecast By Application 10 Market Sizing Analysis & Forecast, By Market Demand 11 Key Market Players Profiles - 22nd Century Group, Inc. - Abattis Bioceuticals Corporation - Advanced Cannabis Solutions - Affinor Growers - Agrisoft Development Group - Arena Pharmaceuticals, Inc. - Canadian Cannabis Corporation - Canna Brands Inc. - Canna Grow Holdings - Cannabics Pharmaceuticals Inc. - Cannabis Sativa Inc. - Cannabis Science, Inc. - Cannabis Therapy Corporation - Cannacare Docs - Cannavest - Dave - Eaze - Endexx Corporation - Equipment & Infrastructure - Frweed Pro - Grassp - Green Technology Solutions Inc. (Gtso) - Gw Pharmaceuticals - Hemp, Inc. - Information Technology - Insys Therapeutics - Leafly - Mass Roots - Meadow - Medbox, Inc. - Medical Marijuana Inc. - Nestdrop - Omnicanna Health Solutions - Otsuka Pharmaceutical Co. Ltd - Plandai Biotechnology - Privateer Holdings, Inc. - Quantum 9 - Sanofi Pharmaceuticals - Surna, Inc. - Tweed Marijuana Inc. - Weedmaps For more information visit http://www.researchandmarkets.com/research/n7...th_america
XXII: 0.84 (+0.01), INSY: 15.69 (+0.05), ARNA: 1.68 (unch)
Abba Medix Builds a Diversified Business
ACCESSWIRE - Wed Jul 08, 7:00AM CDT
WHITEFISH, MT / ACCESSWIRE / July 8, 2015 / Health Canada expects the country's medical marijuana market to dramatically expand over the coming years, growing from 22,000 patients in 2012 to more than 450,000 by 2024, representing a nearly 30% compounded annual growth rate. In dollar terms, the federal agency expects the market to reach approximately $1.2 billion in size, as the market moves from primarily home-growing to industrialized growers approved under the MMPR.
OGI.VN: 1.310 (+0.010), TWD.VN: 1.810 (-0.020)
Nutritional High Poised to Execute on U.S. Edibles Strategy, Hails Canadian Court Ruling
ACCESSWIRE - Tue Jul 07, 7:00AM CDT
WHITEFISH, MT / ACCESSWIRE / July 7, 2015 / Currently exclusively focused on manufacturing and distributing marijuana infused products (MIPs) like edibles and oils, as well as extracts produced with reliable semi automated processes, across U.S. states where such activity is already legal, Nutritional High International (OTCQB: SPLIF) (CSE: NHL) is coming out swinging with universally identifiable branding, featuring marijuana icon Jimi Hendrix on precisely formulated products that will survive longer on the shelf, taking the guesswork out of edibles for retailers and consumers alike. The company's strategy to leverage such iconic branding and roll out a number of marijuana and hemp oil-infused edibles in the U.S. and Canada bearing his likeness, was highlighted by David Posner, president and CEO of Nutritional High, in a recent interview with CannabisFN's Mike Elliott.
NVS: 83.08 (+1.00)
Nutritional High Building a Multi-State Edibles Manufacturing Platform
ACCESSWIRE - Wed Jun 10, 7:01AM CDT
WHITEFISH, MT / ACCESSWIRE / June 10, 2015 / Consistency is key. This is the philosophy under which Nutritional High is building its business from day 1. Headlines abound about marijuana edibles containing anywhere from 0 to 200% of the dosage stated on the package. Some purveyors of edibles, be it homemade brownies or products purchased at dispensaries, find dosing an issue. Testing in Colorado confirms that dosing is a significant challenge for marijuana edible companies as they try to ramp up production, and this is a challenge Nutritional High is taking up.
OGI.VN: 1.310 (+0.010)
Abattis Selects Ingredient Identity as Global Regulatory Management Partner
Marketwired - Mon May 11, 7:36AM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF)(CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, is pleased to announce the engagement of Ingredient Identity, a preeminent regulatory management consulting firm to the Food, Dietary Supplement, Cosmetic and Homeopathic industries globally.
Abattis Appoints Hugh Oswald as Investor Relations
Marketwired - Fri May 01, 10:10AM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF) (CSE: ATT), specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets - some of which will contain cannabinoid compounds, today announced that Hugh Oswald, will assume the role of Investor Relations of Abattis Bioceuticals Corp. effective April 29, 2015.
Abattis Names Michael Yung as Ceo
ACCESSWIRE - Mon Apr 25, 7:06AM CDT
VANCOUVER, BC / ACCESSWIRE / April 25, 2016 / Abattis Bioceuticals Corp. (OTC PINK: ATTBF) (CSE: ATT), (the "Company" or "Abattis"
, today announced that Michael Yung has been named as Chief Executive Officer (CEO) of Abattis Bioceuticals Corp, effective April 18, 2016. He will succeed William (Bill) Fleming, who has resigned his role as CEO and Director to pursue other business interests. Abattis Announces Co-Formulation with Vitagum(TM)
ACCESSWIRE - Mon Apr 18, 7:07AM CDT
VANCOUVER, BC / ACCESSWIRE / April 18, 2016 / Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB : ATTBF) ("Abattis"
through its proposed licensing arrangement with Crimson Capital Group ("Crimson" is pleased to announce that a letter of intent to co-formulate gum products under the brand name Vitagum™ has now been signed. Abattis Receives NPN from Health Canada for Phyto(NOS)(TM)
ACCESSWIRE - Tue Apr 12, 7:08AM CDT
VANCOUVER, BC / ACCESSWIRE / April 12, 2016 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) ("Abattis"
is pleased to announce that it has received a Natural Product Number ("NPN" approval for Phyto(NOS)™. This NPN allows Abattis to manufacture and to sell Phyto(NOS)™ in Canada. Ingredient Identity of Santa Ana, California, completed the claim substantiation report necessary for the sale of Phyto(NOS)™ in the United States. Abattis Agrees to License Its NOXX Botanical Blends Products
ACCESSWIRE - Wed Apr 06, 9:56AM CDT
VANCOUVER, BC / ACCESSWIRE / April 6, 2016 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) ("Abattis'
has agreed to enter a licensing arrangement and marketing partnership with Crimson Capital Group ("Crimson" to commercialize Abattis' NÖXX Botanical Blends Products, which contain Abattis' patent-pending Phyto(NOS)™. Fronsac REIT Announces a Change to the Board of Trustees
Marketwired - Thu Mar 31, 9:45AM CDT
(TSX VENTURE: GAZ.UN) Fronsac Real Estate Investment Trust ("Fronsac REIT" or "Fronsac"
today announced that Guy P. Dancosse and Francois-Olivier Laplante have been appointed to the Fronsac board of trustees. We are pleased to welcome these new trustees to our team and believe that these additions to the board will compliment existing talent and provide added guidance and experience as we continue to grow. IIROC Trade Resumption - ATT
CNW Group - Mon Nov 16, 9:40AM CST
Trading resumes in:
IIROC Trading Halt - ATT
CNW Group - Mon Nov 16, 9:14AM CST
The following issues have been halted by IIROC:
Cabinet Grow: Real Revenue, Real Potential
ACCESSWIRE - Tue Nov 03, 8:20AM CST
SEATTLE, WA / ACCESSWIRE / November 3, 2015 / The U.S. cannabis industry could be worth $35 billion by 2020, according to GreenWave Advisors, if the federal government ended prohibition. In a more conservative model, the analyst believes that the market could still exceed $20 billion, with 12 states and Washington DC legalizing adult-use cannabis and 37 states legalizing medical marijuana. The rapid growth and scale comes from a combination of state programs and home-grow legalization initiatives.
North America Cannabis Market: Focus on Application, Derivative, and Region - Estimation & Forecast, 2015-2020
M2 - Mon Sep 14, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n7wcc2/north_america) has announced the addition of the "North America Cannabis Market: Focus on Application, Derivative, and Region - Estimation & Forecast, 2015-2020" report to their offering. The North America Cannabis market is poised to grow from $ 3.46 billion in 2014 to $20.67 billion in 2020 at an estimated CAGR of 29.80% from 2015 to 2020. Factors like multifaceted applications of cannabis, expansion of licensing strategies, and automated irrigation system among others are driving this market towards growth. This market is also tackling some issues like volatile regulatory framework, absence of market leaders, perception towards marijuana, and environmental hazards among others. Owing to the fragmented supply chain and the presence of black market and perception issues, the cannabis market in North America has been estimated and forecasted strictly for the legal states, both for marijuana and hemp. The following pointers will encompass the scope of the research study and will lend a better understanding to the reader: - The total cannabis market is inclusive of the two primary derivatives namely-marijuana and Industrial Hemp - The market estimation for marijuana includes revenue from the legalized and active markets and Canada, where only medical marijuana is legalized - Certain states have legalized medical and recreational marijuana after 2013, however, there markets are not yet active and therefore, their market shares are not included in the total market size for the benchmark year (2014) - The report includes revenue for the marijuana market for all the active states having market share of above 0.5%. Rest of the state's revenue are clubbed as others - Through the forecast period, the other' states segment will also include the revenue from further states that are anticipated to legalize medical marijuana - The market size by application has been further segmented as applications of marijuana and industrial hemp for better clarity - The report includes the estimates of different entities of the cannabis ecosystem - The report also includes the optimistic revenue estimate for the benchmark year only for the U.S - Tax revenue estimate in case when marijuana is legalized across all the states in the U.S. has also been included Key Topics Covered: 1 Research Methodology, Scope And Coverage 2 Executive Summary 3 Introduction To North American Cannabis Market 4 Key Strategies And Development In The North American Cannabis Market (2013-2015) 5 Market Dynamics 6 North America Cannabis Industry Analysis 7 Regulatory & Legal Framework, Consortiums And Compliances 8 Market Sizing - Estimation, Analysis & Forecast By Derivative 9 Market Sizing- Estimation, Analysis & Forecast By Application 10 Market Sizing Analysis & Forecast, By Market Demand 11 Key Market Players Profiles - 22nd Century Group, Inc. - Abattis Bioceuticals Corporation - Advanced Cannabis Solutions - Affinor Growers - Agrisoft Development Group - Arena Pharmaceuticals, Inc. - Canadian Cannabis Corporation - Canna Brands Inc. - Canna Grow Holdings - Cannabics Pharmaceuticals Inc. - Cannabis Sativa Inc. - Cannabis Science, Inc. - Cannabis Therapy Corporation - Cannacare Docs - Cannavest - Dave - Eaze - Endexx Corporation - Equipment & Infrastructure - Frweed Pro - Grassp - Green Technology Solutions Inc. (Gtso) - Gw Pharmaceuticals - Hemp, Inc. - Information Technology - Insys Therapeutics - Leafly - Mass Roots - Meadow - Medbox, Inc. - Medical Marijuana Inc. - Nestdrop - Omnicanna Health Solutions - Otsuka Pharmaceutical Co. Ltd - Plandai Biotechnology - Privateer Holdings, Inc. - Quantum 9 - Sanofi Pharmaceuticals - Surna, Inc. - Tweed Marijuana Inc. - Weedmaps For more information visit http://www.researchandmarkets.com/research/n7...th_america
XXII: 0.84 (+0.01), INSY: 15.69 (+0.05), ARNA: 1.68 (unch)
Abba Medix Builds a Diversified Business
ACCESSWIRE - Wed Jul 08, 7:00AM CDT
WHITEFISH, MT / ACCESSWIRE / July 8, 2015 / Health Canada expects the country's medical marijuana market to dramatically expand over the coming years, growing from 22,000 patients in 2012 to more than 450,000 by 2024, representing a nearly 30% compounded annual growth rate. In dollar terms, the federal agency expects the market to reach approximately $1.2 billion in size, as the market moves from primarily home-growing to industrialized growers approved under the MMPR.
OGI.VN: 1.310 (+0.010), TWD.VN: 1.810 (-0.020)
Nutritional High Poised to Execute on U.S. Edibles Strategy, Hails Canadian Court Ruling
ACCESSWIRE - Tue Jul 07, 7:00AM CDT
WHITEFISH, MT / ACCESSWIRE / July 7, 2015 / Currently exclusively focused on manufacturing and distributing marijuana infused products (MIPs) like edibles and oils, as well as extracts produced with reliable semi automated processes, across U.S. states where such activity is already legal, Nutritional High International (OTCQB: SPLIF) (CSE: NHL) is coming out swinging with universally identifiable branding, featuring marijuana icon Jimi Hendrix on precisely formulated products that will survive longer on the shelf, taking the guesswork out of edibles for retailers and consumers alike. The company's strategy to leverage such iconic branding and roll out a number of marijuana and hemp oil-infused edibles in the U.S. and Canada bearing his likeness, was highlighted by David Posner, president and CEO of Nutritional High, in a recent interview with CannabisFN's Mike Elliott.
NVS: 83.08 (+1.00)
Nutritional High Building a Multi-State Edibles Manufacturing Platform
ACCESSWIRE - Wed Jun 10, 7:01AM CDT
WHITEFISH, MT / ACCESSWIRE / June 10, 2015 / Consistency is key. This is the philosophy under which Nutritional High is building its business from day 1. Headlines abound about marijuana edibles containing anywhere from 0 to 200% of the dosage stated on the package. Some purveyors of edibles, be it homemade brownies or products purchased at dispensaries, find dosing an issue. Testing in Colorado confirms that dosing is a significant challenge for marijuana edible companies as they try to ramp up production, and this is a challenge Nutritional High is taking up.
OGI.VN: 1.310 (+0.010)
Abattis Selects Ingredient Identity as Global Regulatory Management Partner
Marketwired - Mon May 11, 7:36AM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF)(CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, is pleased to announce the engagement of Ingredient Identity, a preeminent regulatory management consulting firm to the Food, Dietary Supplement, Cosmetic and Homeopathic industries globally. Abattis Appoints Hugh Oswald as Investor Relations
Marketwired - Fri May 01, 10:10AM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets - some of which will contain cannabinoid compounds, today announced that Hugh Oswald, will assume the role of Investor Relations of Abattis Bioceuticals Corp. effective April 29, 2015. 
